Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 8/20 | 0.62 |
| ▸ | SLC2A1 | P11166 | 12/20 | 0.61 |
| ▸ | SLC2A3 | P11169 | 12/20 | 0.61 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20953086 | 0.92 | SLC2A1 (0.71) | ROCK2SLC2A1SLC2A3ROCK1 | |
| SCHEMBL20953063 | 0.91 | SLC2A1 (0.72) | ROCK2SLC2A1SLC2A3ROCK1 | |
| SCHEMBL20953080 | 0.91 | SLC2A1 (0.72) | ROCK2SLC2A1SLC2A3ROCK1 | |
| SCHEMBL18343367 | 0.90 | SLC2A1 (0.71) | ROCK2SLC2A1SLC2A3ROCK1 | |
| SCHEMBL18343187 | 0.86 | ROCK2 (0.63) | ROCK2SLC2A1SLC2A3ROCK1 | |
| SCHEMBL18343208 | 0.86 | SLC2A3 (0.69) | ROCK2SLC2A1SLC2A3ROCK1 | |
| SCHEMBL18343302 | 0.85 | ROCK2 (0.59) | ROCK2SLC2A1SLC2A3ROCK1 | |
| SCHEMBL18343244 | 0.85 | ROCK2 (0.60) | ROCK2SLC2A1SLC2A3ROCK1 | |
| SCHEMBL21681317 | 0.85 | SLC2A1 (0.60) | SLC2A1SLC2A3 | |
| SCHEMBL21707975 | 0.85 | SLC2A1 (0.60) | SLC2A1SLC2A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10988484-B2 | Glucose uptake inhibitors | KADMON CORPORATION, LLC (US) | 2021-04-27 | — | — | US | disclosed |
| US-10988484-B2 | Glucose uptake inhibitors | KADMON CORPORATION, LLC (US) | 2021-04-27 | — | — | US | disclosed |
| US-20190315772-A1 | GLUCOSE UPTAKE INHIBITORS | KADMON CORP LLC (US) | 2019-10-17 | — | — | US | disclosed |
| US-20190315772-A1 | GLUCOSE UPTAKE INHIBITORS | KADMON CORP LLC (US) | 2019-10-17 | — | — | US | disclosed |
| US-10273248-B2 | Glucose uptake inhibitors | Kadmon Corportion, LLC (US) | 2019-04-30 | — | — | US | disclosed |
| US-10273248-B2 | Glucose uptake inhibitors | Kadmon Corportion, LLC (US) | 2019-04-30 | — | — | US | disclosed |
| US-20180298029-A1 | GLUCOSE UPTAKE INHIBITORS | KADMON CORPORATION LLC (US) | 2018-10-18 | — | — | US | disclosed |
| EP-3313825-A1 | GLUCOSE UPTAKE INHIBITORS | Kadmon Corporation, LLC (US) | 2018-05-02 | — | — | EP | disclosed |
| WO-2016210330-A1 | GLUCOSE UPTAKE INHIBITORS | KADMON CORPORATION, LLC (US) | 2016-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180298029-A1 | GLUCOSE UPTAKE INHIBITORS | SLC2A1, SLC2A2, SLC2A4 | ROCK2 4260/4885SLC2A1 1/4885SLC2A3 4/4885 |
| US-10988484-B2 | Glucose uptake inhibitors | SLC2A1, SLC2A2, SLC2A4 | ROCK2 4305/4885SLC2A1 1/4885SLC2A3 4/4885 |
| US-20190315772-A1 | GLUCOSE UPTAKE INHIBITORS | SLC2A1, SLC2A4, SLC2A2 | ROCK2 3943/4885SLC2A1 1/4885SLC2A3 4/4885 |
| US-10273248-B2 | Glucose uptake inhibitors | SLC2A1, SLC2A2, SLC2A4 | ROCK2 4260/4885SLC2A1 1/4885SLC2A3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.